GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

117.27 1.86 −1.56%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a

GRAIL, Inc. 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 6, 2026: 10 added · 1 removed · 3 modified

14 more changes in this Item, word by word, in Powerpack.